Home / Health / Grimsby Man's Tumour Battle Sparks Fundraising Hope
Grimsby Man's Tumour Battle Sparks Fundraising Hope
7 Sep
Summary
- Scott Walker, 42, was diagnosed with a brain tumour in January 2026.
- His family is fundraising for Brain Tumour Research via a sponsored walk.
- Treatment is complicated by the tumour's critical location in the brain stem.

Scott Walker, a 42-year-old from Grimsby, has been diagnosed with a brain tumour. His symptoms, initially dismissed as a shoulder injury, progressed to tingling and weakness in his arm and leg. In January 2026, an MRI at Diana, Princess of Wales Hospital confirmed a brain tumour.
Further imaging at Hull Royal Infirmary suggested a low-grade glioma. However, after a radiotherapy planning scan, a subsequent MRI revealed the tumour had spread, leading his medical team to classify it as a grade 4 midline glioma, a more aggressive form. Due to its critical location in the brain stem, a biopsy to determine the exact grade was not possible, leading to significant uncertainty.
Scott has undergone radiotherapy and is currently receiving daily oral chemotherapy. He has had to surrender his driving license and stop working due to worsened mobility. His wife, Kerry, and stepdaughter, Molly, are raising funds for Brain Tumour Research, a charity focused on finding a cure.
Molly and Kerry are participating in the Walk of Hope on Saturday, September 26, 2026, at Chatsworth. They initially aimed for £200 but quickly surpassed it, now targeting £500. Their efforts aim to raise awareness and funds for research, highlighting that brain cancer is the leading cancer killer of people under 40 but receives insufficient funding.
Brain Tumour Research funds research at dedicated UK centres and advocates for increased national investment. The charity seeks an annual spend of £45 million to improve survival rates and patient outcomes. Scientists at the Brain Tumour Research Centre of Excellence at the University of Nottingham are using advanced techniques, including artificial intelligence, to understand tumour recurrence and accelerate the development of new treatments.